Sangamo Therapeutics, Inc. (SGMOQ)
0.1662
0.00 (0.00%)
USD |
OTCM |
Sep 03, 16:00
Sangamo Therapeutics Cash from Operations (Annual) : -97.21M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -97.21M |
| December 31, 2024 | -67.14M |
| December 31, 2023 | -224.84M |
| December 31, 2022 | -223.63M |
| December 31, 2021 | -233.25M |
| December 31, 2020 | 169.88M |
| December 31, 2019 | -144.40M |
| December 31, 2018 | 37.15M |
| December 31, 2017 | 11.18M |
| December 31, 2016 | -65.88M |
| December 31, 2015 | -33.72M |
| December 31, 2014 | -5.675M |
| December 31, 2013 | -19.16M |
| December 31, 2012 | -8.082M |
| Date | Value |
|---|---|
| December 31, 2011 | -25.90M |
| December 31, 2010 | -23.93M |
| December 31, 2009 | -6.137M |
| December 31, 2008 | -17.34M |
| December 31, 2007 | -16.07M |
| December 31, 2006 | -14.48M |
| December 31, 2005 | -4.069M |
| December 31, 2004 | -10.16M |
| December 31, 2003 | -7.44M |
| December 31, 2002 | -9.672M |
| December 31, 2001 | -6.107M |
| December 31, 2000 | -2.454M |
| December 31, 1999 | -2.444M |
| December 31, 1998 | -3.162M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 179.55M |
| Oncolytics Biotech, Inc. | -20.11M |
| Sarepta Therapeutics, Inc. | -222.54M |
| Anixa Biosciences, Inc. | -7.173M |
| Vicapsys Life Sciences, Inc. | -0.0215M |